Common questions about Flacort (FAQ)
Q: Is Flacort the same type of medicine as prednisolone or dexamethasone?
A: Flacort is categorized as a synthetic glucocorticoid, which is a type of corticosteroid, placing it in the same pharmacological class as medicines like prednisolone. Official documents indicate that Deflazacort is a derivative of prednisolone. This specific chemical difference results in distinctions in how the body processes the medicine and its physiological effects.
Q: Can Flacort be taken indefinitely, or is it only for short-term use?
A: Regulatory documents state that the total duration of treatment depends on the specific medical condition being addressed. For long-term use, the dose requires gradual reduction (tapering) upon discontinuation to help avoid withdrawal effects, as noted in regulatory guidelines. Prolonged use is generally associated with a greater chance of experiencing specific side effects.
Q: Does Flacort cause changes in mood or sleep patterns?
A: Official product labeling for Flacort includes warnings regarding potential behavioral and mood disturbances. Side effects that have been reported include irritability, mood swings, and feelings of depression. Difficulty sleeping, known as insomnia, is also listed as a possible side effect in the official documents.
Q: How quickly should I expect to notice the effects of Flacort?
A: Flacort is designed to be quickly metabolized by the body’s plasma enzymes into its active form. This active metabolite reaches its highest concentration in the bloodstream approximately one to two hours after being taken. However, regulatory summaries do not specifically quantify the time required before the anti-inflammatory effects become clinically noticeable.
Q: If I miss a dose of Flacort, what is the generally accepted advice?
A: Regulatory patient guidance advises that if a dose is missed, it should be taken as soon as remembered, provided it is not almost time for the next dose. It is officially noted that taking two doses together is not permitted.
Q: Are there any specific foods or drinks to avoid while taking Flacort?
A: The official product label explicitly prohibits the co-administration of grapefruit or grapefruit juice, stating that it must not be used to mix or take the medicine. General regulatory guidance regarding avoidance of other specific foods or common drinks is not broadly detailed in the prescribing information.
Q: What should be done if an allergic reaction is suspected after taking Flacort?
A: Official safety guidance notes that if signs of a serious allergic reaction are suspected, seeking immediate medical attention is advised. These signs can include difficulty breathing or swallowing, swelling of the face, tongue, or throat, hives, or a fast heart rate. Hypersensitivity to Flacort is an absolute contraindication for its use.
Q: Are there different forms or strengths of Flacort, and what does that depend on?
A: Flacort is manufactured in two main pharmaceutical forms: tablets and a liquid oral suspension. Official regulatory documents indicate that the tablet form is available in several different strengths, such as 6 mg, 18 mg, 30 mg, and 36 mg. Official documents list multiple available strengths and forms.
Q: Can Flacort affect the results of blood tests or medical procedures?
A: Flacort is known to modulate the body’s metabolism and hormonal system. Regulatory documents note that the medicine can cause hyperglycemia (high blood sugar) and HPA axis suppression. Due to these effects, the official information suggests that blood or urine tests may be required to monitor for such changes, indicating a potential alteration in certain test results.
Q: Can Flacort be used by older adults, and what does the research say?
A: Official guidance indicates that no special precautions are necessary for older adults beyond the general recommendations for any patient taking a glucocorticoid. However, regulatory documents do note that the common adverse effects associated with systemic corticosteroids may lead to more serious consequences in older age.
Q: Is Flacort known to cause vision problems or changes to eye health?
A: Official prescribing information states that the prolonged use of Flacort has been associated with changes to eye health. These reported changes include the potential development of posterior subcapsular cataracts and glaucoma. Because of these potential effects, routine eye examinations are noted as a safety consideration for patients receiving chronic therapy.
Q: What is the official information regarding driving or operating machinery while taking Flacort?
A: While regulatory documents do not provide a direct blanket restriction on driving or operating machinery, the official labeling does list certain side effects that could potentially affect these activities. These include dizziness, changes in mood, and blurred vision.
Q: What is the official advice on when to notify a doctor about a side effect from Flacort?
A: Official guidance advises patients that they should report any side effect that is bothersome or persistent. It further advises seeking assistance for serious symptoms, such as signs of infection, changes in vision, or severe changes in mood or behavior.
Q: Is it necessary to carry an identification card when taking Flacort, as mentioned for some corticosteroids?
A: Official patient information for Flacort and similar systemic corticosteroids sometimes recommends carrying a 'Steroid treatment' identification card. This card is intended to provide clear, essential information to other medical professionals in an emergency, especially when a patient is receiving long-term treatment.
Q: Is there a specific mechanism by which Flacort helps reduce inflammation?
A: Flacort works by first being converted into an active metabolite within the body. This active form binds to specific cell receptors, which then fundamentally alters gene activity. This action reduces the body’s production of inflammatory chemicals, resulting in a comprehensive anti-inflammatory and immunosuppressive effect.
Q: How is Flacort typically processed and eliminated by the body, according to pharmacokinetics data?
A: Pharmacokinetics data confirms that Flacort is rapidly metabolized by plasma enzymes into its active form. This active metabolite is then primarily processed and eliminated from the body through the kidneys. The active substance has an elimination half-life of approximately 1.5 to 2 hours.
